Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gicitinib
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Zhengzhou University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gicitinib (gicitinib hydrochloride) is a small molecule Janus kinase (JAK) inhibitor being investigated for the treatment of chronic graft-versus-host disease (cGVHD). It is administered orally in tablet form and is being evaluated as a first-line systemic therapy in combination with standard immunosuppressive regimens for patients with moderate to severe cGVHD following allogeneic hematopoietic stem cell transplantation. The drug's mechanism of action involves the inhibition of JAK signaling pathways, which are critical in the mediation of inflammatory cytokines and the immune response underlying GVHD pathogenesis. Note: The name 'gicitinib' appears to be a phonetic misspelling or variant of itacitinib (吉西替尼) used in the provided clinical trial context, and the drug does not appear to be a recognized international nonproprietary name (INN).
- Other names
- gicitinib hydrochloride
02
Targets
Beyond the preview
Go deeper on gicitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gicitinib.